PARTNERSHIP OPPORTUNITIES

LATITUDE’s formulation expertise has led to internal product development activities that focus on addressing areas of unmet medical need through improving the formulation of existing drugs. These efforts include making these existing drugs significantly safer, more stable and/or easier-to-use, and often result in associated new intellectual property.  Such re-formulations are designed to be eligible for the fast-track 505(b)(2) NDA, offering considerable time and cost savings for FDA approval. 


LATITUDE seeks to out-license its 505(b)(2) programs to partners for further development and/or commercialization of these drugs. LATITUDE’s currently available 505(b)(2) product candidates include:

LATITUDE has also applied its formulation expertise to develop other novel formulations of known drugs in new dosage formats:

For further information on these Licensing Opportunities, click here.